What is the Origin of TRIIM Trial?

The trial was conceived and executed by a team of researchers focused on the intersection of endocrinology, immunology, and aging biology. The specific regimen was rationally designed to promote thymus regeneration, a gland central to immune function that typically atrophies with age. The acronym TRIIM was created to summarize the core biological goals of the intervention.

What is the Mechanism of TRIIM Trial?

The therapeutic regimen was designed to target multiple pathways implicated in aging. Growth hormone was included to stimulate thymic tissue regeneration, while DHEA was intended to support the overall endocrine environment. Metformin, a common diabetes drug, was incorporated for its known anti-aging and insulin-sensitizing effects, aiming to mitigate potential adverse effects of growth hormone on glucose metabolism. The combined action of these agents was hypothesized to reset the epigenetic clock, thereby improving cellular and immune function.

TRIIM Trial

Meaning

The Thymus Regeneration, Immunorestoration, and Insulin Mitigation (TRIIM) Trial was a small, proof-of-concept clinical study that investigated a combination of growth hormone, DHEA, and metformin to reverse aspects of biological aging in a cohort of older men. The primary outcome measured was the epigenetic clock, a molecular marker of biological age based on DNA methylation patterns. The trial’s findings suggested that this multi-drug regimen could potentially reverse epigenetic age, generating significant interest in the field of longevity and regenerative medicine.